ClinicalTrials.gg
CompletedNCT02781558Updated Nov 27, 2018Results posted

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

A Phase 2 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 28 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-27.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
41st of 174
204 · median 78
Started
2016
with 13 others
Phase 2
47 of 174
none open now
Registered
164th of 174
by date
Lead sponsor
15 of 174
Gilead Sciences

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 41st largest by enrollment, is one of 14 that started in 2016, is one of 47 in phase 2, and was the 164th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with chronic genotype 3 hepatitis C virus (HCV) infection and compensated cirrhosis.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Willing and able to provide written
  • Individuals with chronic genotype 3 infection and compensated cirrhosis
  • Individuals with or without -1 coinfection

Key Exclusion Criteria:

  • History of illness or any other medical disorder that may interfere with individual's treatment assessment or compliance with the protocol
  • Co-infection with active virus
  • Laboratory results outside the acceptable ranges at screening
  • Pregnant or nursing female
  • Chronic liver disease not caused by HCV

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    SOF/VEL

    SOF/VEL FDC for 12 weeks

    Drug: SOF/VEL

  • Experimental
    SOF/VEL + RBV

    SOF/VEL FDC + RBV for 12 weeks

    Drug: SOF/VEL · Drug: RBV

Interventions

  • DrugSOF/VEL

    Drug pages: Sofosbuvir · Velpatasvir

    400/100 mg FDC tablet administered orally once daily

    Also known as: GS-7977/GS-5816, Epclusa®

  • DrugRBV

    RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event

    Time frame: Posttreatment Week 12

Secondary outcomes

  1. Percentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)

    SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants Who Have HCV RNA < LLOQ at Week 2

    Time frame: Week 2

  3. Percentage of Participants Who Have HCV RNA < LLOQ at Week 4

    Time frame: Week 4

  4. Percentage of Participants Who Have HCV RNA < LLOQ at Week 8

    Time frame: Week 8

  5. Percentage of Participants Who Have HCV RNA < LLOQ at Week 12

    Time frame: Week 12

  6. HCV RNA at Week 2

    Time frame: Week 2

  7. HCV RNA at Week 4

    Time frame: Week 4

  8. HCV RNA at Week 8

    Time frame: Week 8

  9. HCV RNA at Week 12

    Time frame: Week 12

  10. Change From Baseline in HCV RNA at Week 2

    Time frame: Baseline; Week 2

  11. Change From Baseline in HCV RNA at Week 4

    Time frame: Baseline; Week 4

  12. Change From Baseline in HCV RNA at Week 8

    Time frame: Baseline; Week 8

  13. Change From Baseline in HCV RNA at Week 12

    Time frame: Baseline; Week 12

  14. Percentage of Participants With Virologic Failure

    Virologic failure was defined as * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ on 2 consecutive measurements while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement

    Time frame: Up to Posttreatment Week 12

07

Results

Posted Oct 30, 2018

Participant flow

Participants were enrolled at study sites in Spain. The first participant was screened on 29 July 2016. The last study visit occurred on 27 October 2017.

Participant flow — Overall Study
MilestoneSOF/VELSOF/VEL + RBV
Started101103
Completed98101
Not completed32
Withdrew: Lost to follow-up22
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)91.1 (83.8 to 95.8)96.1 (90.4 to 98.9)
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event
Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants Who Permanently Discontinued Any Study Drug (Which Included SOF/VEL and RBV) Due to Any Adverse Event1.01.9
SecondaryPercentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)

SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants Who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)93.1 (86.2 to 97.2)97.1 (91.7 to 99.4)
SecondaryPercentage of Participants Who Have HCV RNA < LLOQ at Week 2
Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HCV RNA < LLOQ at Week 2
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants Who Have HCV RNA < LLOQ at Week 251.0 (40.8 to 61.1)44.7 (34.9 to 54.8)
SecondaryPercentage of Participants Who Have HCV RNA < LLOQ at Week 4
Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HCV RNA < LLOQ at Week 4
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants Who Have HCV RNA < LLOQ at Week 485.0 (76.5 to 91.4)90.3 (82.9 to 95.2)
SecondaryPercentage of Participants Who Have HCV RNA < LLOQ at Week 8
Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HCV RNA < LLOQ at Week 8
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants Who Have HCV RNA < LLOQ at Week 899.0 (94.6 to 100.0)100.0 (96.4 to 100.0)
SecondaryPercentage of Participants Who Have HCV RNA < LLOQ at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HCV RNA < LLOQ at Week 12
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants Who Have HCV RNA < LLOQ at Week 1299.0 (94.6 to 100.0)100.0 (96.4 to 100.0)
SecondaryHCV RNA at Week 2
Time frame:
Week 2
Reported as:
Mean · log10 IU/mL
HCV RNA at Week 2
log10 IU/mLSOF/VELSOF/VEL + RBV
HCV RNA at Week 21.52 ± 0.5131.47 ± 0.413
SecondaryHCV RNA at Week 4
Time frame:
Week 4
Reported as:
Mean · log10 IU/mL
HCV RNA at Week 4
log10 IU/mLSOF/VELSOF/VEL + RBV
HCV RNA at Week 41.22 ± 0.2571.19 ± 0.152
SecondaryHCV RNA at Week 8
Time frame:
Week 8
Reported as:
Mean · log10 IU/mL
HCV RNA at Week 8
log10 IU/mLSOF/VELSOF/VEL + RBV
HCV RNA at Week 81.15 ± 0.0401.15 ± 0.000
SecondaryHCV RNA at Week 12
Time frame:
Week 12
Reported as:
Mean · log10 IU/mL
HCV RNA at Week 12
log10 IU/mLSOF/VELSOF/VEL + RBV
HCV RNA at Week 121.15 ± 0.0181.15 ± 0.000
SecondaryChange From Baseline in HCV RNA at Week 2
Time frame:
Baseline; Week 2
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 2
log10 IU/mLSOF/VELSOF/VEL + RBV
Change From Baseline in HCV RNA at Week 2-4.67 ± 0.627-4.80 ± 0.580
SecondaryChange From Baseline in HCV RNA at Week 4
Time frame:
Baseline; Week 4
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 4
log10 IU/mLSOF/VELSOF/VEL + RBV
Change From Baseline in HCV RNA at Week 4-4.96 ± 0.641-5.09 ± 0.559
SecondaryChange From Baseline in HCV RNA at Week 8
Time frame:
Baseline; Week 8
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 8
log10 IU/mLSOF/VELSOF/VEL + RBV
Change From Baseline in HCV RNA at Week 8-5.04 ± 0.638-5.13 ± 0.565
SecondaryChange From Baseline in HCV RNA at Week 12
Time frame:
Baseline; Week 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 12
log10 IU/mLSOF/VELSOF/VEL + RBV
Change From Baseline in HCV RNA at Week 12-5.04 ± 0.640-5.13 ± 0.568
SecondaryPercentage of Participants With Virologic Failure

Virologic failure was defined as * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ on 2 consecutive measurements while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement

Time frame:
Up to Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure
percentage of participantsSOF/VELSOF/VEL + RBV
Percentage of Participants With Virologic Failure5.91.9

Adverse events

Collected over Up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOF/VEL0/101 (0%)4/101 (4%)24/101 (23.8%)
SOF/VEL + RBV0/103 (0%)2/103 (1.9%)55/103 (53.4%)
Most frequent serious events
Most frequent serious events
EventSOF/VELSOF/VEL + RBV
PharyngotonsillitisInfections and infestations1/1010/103
Urinary tract infectionInfections and infestations1/1010/103
Accident at workInjury, poisoning and procedural complications1/1010/103
Limb injuryInjury, poisoning and procedural complications1/1010/103
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1010/103
Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1011/103
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1011/103
Most frequent other events
Most frequent other events
EventSOF/VELSOF/VEL + RBV
AstheniaGeneral disorders12/10128/103
HeadacheNervous system disorders8/10125/103
InsomniaPsychiatric disorders1/10112/103
PruritusSkin and subcutaneous tissue disorders2/1019/103
Back painMusculoskeletal and connective tissue disorders7/1014/103
NauseaGastrointestinal disorders2/1016/103

Baseline characteristics

Safety Analysis Set: participants who took at least 1 dose of any study drug

Age, Continuous
Age, Continuous(years)SOF/VELSOF/VEL + RBVTotal
Mean51 ± 7.351 ± 7.651 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)SOF/VELSOF/VEL + RBVTotal
Female261642
Male7587162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOF/VELSOF/VEL + RBVTotal
White8495179
Asian17825
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOF/VELSOF/VEL + RBVTotal
Hispanic or Latino91019
Not Hispanic or Latino9293185
IL28B
IL28B(Participants)SOF/VELSOF/VEL + RBVTotal
CC6453117
Non-CC365086
Missing101
HCV RNA
HCV RNA(log10 IU/mL)SOF/VELSOF/VEL + RBVTotal
Mean6.2 ± 0.646.3 ± 0.566.2 ± 0.60
HCV RNA Category
HCV RNA Category(Participants)SOF/VELSOF/VEL + RBVTotal
< 800,000 IU/mL322456
≥ 800,000 IU/mL6979148
08

Study locations

28 sites
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria, Spain
  • Hospital Universitario Fundacion Alcorcon
    Alcorcon, Spain
  • Hospital General Universitario De Alicante
    Alicante, Spain
  • Complejo Hospitalario Torrecárdenas
    Almeria, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Spain
  • Hospital Universitario Valle Hebron
    Barcelona, 8035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
  • Servei de d'Aparell Digestiu Corporació Sanitària Parc Taulí
    Barcelona, Spain
  • Reina Sofía University Hospital
    Cordoba, Spain
  • Hospital Universitario de A Coruña
    Coruna, Spain
  • Hospital Puerta De Hierro Majadahonda
    Madrid, Spain
  • Hospital Ramón y Cajal
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Universitario Virgen de la Victoria
    Malaga, Spain
  • Hospital Universitario Virgen De La Arrixaca
    Murcia, Spain
  • Hospital Universitario Central de asturias
    Oviedo, Spain
  • Complexo Hospitalario Universitario de Montecelo
    Pontevedra, Spain
  • Hospital Universitario Donostia
    San Sebastian, Spain
  • Hospital Univ. NuestraSeñora Candelaria
    Santa Cruz de Tenerife, Spain
  • Hospital de Valme
    Sevilla, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, Spain
  • Hospital Clinico Universitario
    Valencia, Spain
  • Hospital General Valencia
    Valencia, Spain
  • La Fe Hospital
    Valencia, Spain
  • Hospital Universitario Alvaro Cunqueiro
    Vigo, Spain
  • Hospital Clinico Universitario
    Zaragoza, Spain
09

References and documents

Publications

  • Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrion JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27. PubMed 29958855 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Oct 2017, 14 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
May 24, 2016
StartActual
Jul 29, 2016
Primary completionActual
Oct 6, 2017
CompletionActual
Oct 27, 2017
Results first posted
Oct 30, 2018
Last update
Nov 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02781558
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 24, 2016
Start date
Jul 29, 2016
Primary completion
Oct 6, 2017
Completion
Oct 27, 2017
Results posted
Oct 30, 2018
Last update
Nov 27, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion